ClinicalTrials.gg
CompletedNCT03678688Updated Nov 18, 2023Results posted

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

A Phase 1/2 interventional study of 10 mg OPC-167832 and 30 mg OPC-167832 in Pulmonary TB, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 3 sites in South Africa. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing OPC-67683 in Tuberculosis, Pulmonary — 1 open to participants now, 4 under way, 2 of them phase 3. OPC-67683 · Tuberculosis, Pulmonary.

Enrollment
7th of 10
122 · median 208
Started
2018
the only one that year
Registered
4th of 10
by date
Lead sponsor
2 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, this one is the 7th largest by enrollment, is the only one that started in 2018, and was the 4th registered.

Tuberculosis, Pulmonary

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

1 of the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About OPC-67683

OPC-67683: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).

03

Conditions studied

  • Pulmonary TB
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written, prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements of the trial.
  • Male or female participants between 18 and 64 years of age (inclusive) at the screening visit.
  • ≥ 16.0 and ≤ 32.0 kilograms per meters squared (kg/m\^2) (inclusive) at the screening visit.
  • Newly diagnosed, uncomplicated, drug-susceptible pulmonary TB.
  • Microscopy performed on a sputum smear at screening indicates presence of acid-fast bacilli (at least 1+).
  • Able to produce an adequate volume of sputum (approximately 10 millilitres (mL) or more estimated overnight production).
  • Female participants of must agree to use 2 different approved methods of or remain abstinent throughout the participation in the trial and for 12 weeks after the last dose of trial treatment ( medicinal product (IMP) or RHEZ).
  • Male participants must agree to use 2 different approved methods of birth control or remain abstinent throughout the participation in the trial and for 12 weeks after the last dose of trial treatment (IMP or RHEZ).

Exclusion criteria

Exclusion Criteria:

  • Participants are known or suspected of having resistance to rifampicin, isoniazid, ethambutol, or pyrazinamide using any combination of Xpert Mycobacterium tuberculosis/Rifampin (MTB/RIF), line probe assay, culture, and/or epidemiologic history at screening.
  • Poor general condition where no delay in treatment can be tolerated or where immediate hospital admission is warranted.
  • Evidence of metabolic (including ongoing or current hypokalemia), gastrointestinal, neurological, psychiatric, endocrine or liver (e.g., and C) disease; ; or other abnormalities (other than the indication being studied).
  • History of or current clinically relevant cardiovascular disorder such as heart failure, coronary heart disease, hypertension, arrhythmia or symptom strongly suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia or status after myocardial infarction.
  • Known bleeding disorders or family history of bleeding disorders.
  • Any diseases or conditions in which the use of delamanid, rifampicin, isoniazid, pyrazinamide, ethambutol, or Bedaquiline is .
  • Any prior treatment for M. tuberculosis within the past 3 years.
  • Any treatment with a drug active against M. tuberculosis (e.g., quinolones) within the 3 months prior to screening.
  • Clinical evidence of severe extrapulmonary TB (e.g., miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis).
  • Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as severe by the investigator (other than TB). In particular any underlying condition that could interfere with the assessment of x-ray images, sputum collection, or interpretation of sputum findings, or otherwise compromise the subject's participation in the trial.
  • Any renal impairment characterized by serum of \<60 millilitres per minute (mL/min), or hepatic impairment characterized by , aspartate transaminase, or total >1.5 x (ULN) of the clinical laboratory reference range at screening.
  • For Stage 1, participants who are (HIV) positive are excluded. For Stage 2, participants with HIV co-infection who are on antiretroviral drugs during screening or with \<500/ millimeters cubed (mm\^3) are excluded.
  • Changes in the (ECG) such as >450 milliseconds (msec), atrioventricular block II or III, bi-fasicular block, at screening or current history of clinically significant ventricular arrhythmias. Other ECG changes if considered clinically significant by the investigator.
  • Participants receiving any of the prohibited medications within the specified periods or who would be likely to require prohibited concomitant therapy during the trial.
  • Female participants who are breast-feeding or who have a positive pregnancy test result prior to receiving the first dose of IMP or RHEZ on Day 1.
  • History of significant drug and/or alcohol abuse within 2 years prior to screening.
  • History of or current hepatitis or carriers of HBsAg and/or anti-.
  • Positive urine or blood alcohol test and/or urine drug screen for substance abuse at screening (not including cannabinoids).
  • History of having taken an drug within 30 days preceding trial entry (ie, prior to screening).
  • A history of difficulty in donating blood.
  • Donation of blood or plasma within 30 days prior to dosing.
  • Consumption of alcohol and/or grapefruit, grapefruit juice, Seville oranges, or Seville orange juice and related products within 72 hours prior to the first dose of IMP or RHEZ on Day 1.
  • History of serious mental disorders that, in the opinion of the investigator, would exclude the subject from participating in this trial.
  • Any known prior exposure to OPC-167832, delamanid or Bedaquiline.
  • Participants with significant medical comorbidities that in the opinion of the investigator, should not participate in the trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Active comparator
    Stage 1: RHEZ

    Participants received a single dose of RHEZ (each tablet containing 150 milligrams (mg) rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, once daily (QD) from Day 1 through Day 20.

    Drug: RHEZ

  • Experimental
    Stage 1: 10 mg OPC-167832

    Participants received OPC-167832, 10 mg, orally, QD, from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 10 mg OPC-167832

  • Experimental
    Stage 1: 30 mg OPC-167832

    Participants received OPC-167832, 30 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 30 mg OPC-167832

  • Experimental
    Stage 1: 90 mg OPC-167832

    Participants received OPC-167832, 90 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 90 mg OPC-167832

  • Experimental
    Stage 1: 3 mg OPC-167832

    Participants received OPC-167832, 3 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 3 mg OPC-167832

  • Experimental
    Stage 2: 30 mg OPC-167832 + 300 mg Delamanid

    Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 30 mg OPC-167832 + 300 mg delamanid

  • Experimental
    Stage 2: 30 mg OPC-167832 + 400 mg Bedaquiline (BDQ)

    Participants received OPC-167832, 30 mg, in combination with BDQ, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, QD, orally from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 30 mg OPC-167832 + 400 mg BDQ

  • Experimental
    Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ

    Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg and BDQ, 400 mg, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, orally, QD from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.

    Drug: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ

  • Active comparator
    Stage 2: RHEZ

    Participants received a single dose of RHEZ (each tablet containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, QD, from Day 1 through Day 20.

    Drug: RHEZ

Interventions

  • Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.

  • Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.

  • Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.

  • Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.

  • DrugRHEZ

    RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight: * Participants weighing 30 to 37 kg received 2 tablets per day * Participants weighing 38 to 54 kg received 3 tablets per day * Participants weighing 55 to 70 kg received 4 tablets per day * Participants weighing \> 70 kg received 5 tablets per day

  • Drug30 mg OPC-167832 + 300 mg delamanid

    Drug pages: Quabodepistat · OPC-67683

    Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.

  • Drug30 mg OPC-167832 + 400 mg BDQ

    Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.

  • Drug30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ

    Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.

06

What researchers measure

Primary outcomes

  1. Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)

    Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.

    Time frame: Baseline to Day 14

  2. Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  3. Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  4. Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  5. Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  6. Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  7. Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  8. Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable from non-compartmental analysis (NCA). The values reported for this outcome measure (OM) are estimates and not actual observed data.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  9. Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  10. Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  11. Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  12. Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  13. Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  14. Stage 2: Cmax of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  15. Stage 2: Cmax,ss of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  16. Stage 2: Tmax of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  17. Stage 2: Tmax of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  18. Stage 2: AUC0-24 of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  19. Stage 2: AUCτ of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  20. Stage 2: T1/2,z of Delamanid

    T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  21. Stage 2: CLss/F of Delamanid From Plasma

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  22. Stage 2: RCmax of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  23. Stage 2: RAUC of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  24. Stage 2: Cmax/Dose of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  25. Stage 2: AUCτ/Dose of Delamanid

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  26. Stage 2: Cmax of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  27. Stage 2: Cmax,ss of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  28. Stage 2: Tmax of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  29. Stage 2: Tmax of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  30. Stage 2: AUC0-24 of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  31. Stage 2: AUCτ of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  32. Stage 2: T1/2,z of Bedaquiline

    T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  33. Stage 2: CLss/F of BDQ From Plasma

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  34. Stage 2: Cmax/Dose of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  35. Stage 2: AUCτ/Dose of Bedaquiline

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  36. Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all AEs which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.

    Time frame: From first dose of study drug to end of follow up period (up to 34 days)

  37. Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Vital Sign Values

    Time frame: From first dose of study drug to end of follow up period (up to 34 days)

  38. Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    Time frame: From first dose of study drug to end of follow up period (up to 34 days)

Secondary outcomes

  1. Stage 1 and Stage 2: Change From Baseline in Lipoarabinomannan (LAM) in the Mycobacteria Growth Indicator Tube® (MGIT) System

    LAM is a key component of the M. tuberculosis cell wall and the decline of sputum LAM concentrations has been shown to correlate closely with CFU decreases in sputum counted on agar media during the first 14 days of TB treatment. Sputum LAM concentration at each collection time point was measured using MGIT system. Baseline LAM was calculated as the log 10 of the average from Day -2 and Day -1 and the change from baseline in log10 was calculated as post-baseline minus baseline for each parameter.

    Time frame: Baseline to Day 14

  2. Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System

    TTD is the time from start of inoculation of a sputum sample until a MGIT machine detects a positive signal during the 42-day incubation period. One TTD measurement, reported in days and hours was taken at each of the visits at Days -2, -1, 2, 4, 6, 8, 10, 12 and 14. TTD values were then calculated as "days + hours/24" to be used in deriving the analysis values of TTD. Each sample collected from Day -2 to Day 14 were inoculated for 42 days. Baseline TTD was derived using Day -2 and Day -1 MGIT culture with a pure positive result for Mycobacterium tuberculosis. Postbaseline TTD analysis values from Day 1 were derived based on the MGIT culture result as follows: If MGIT culture result was negative for MTB complex, TTD was set to 42 days; If the MGIT culture was pure positive for MTB, but the TTD took longer than 42 days, TTD was capped at 42 days.

    Time frame: Day 1 to Day 14 of treatment period + 42 days of inoculation period (up to 56 days)

  3. Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA

    Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.

    Time frame: Baseline to Day 14

  4. Stage 2: Plasma Concentration of Rifampin

    Time frame: 2 hours and 6 hours post-dose on Day 14

  5. Stage 1: Plasma Concentration of Isoniazid

    Time frame: 2 hours and 6 hours post-dose on Day 14

  6. Stage 2: Cmax of DM-6705

    DM-6705 is a metabolite of delamanid.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  7. Stage 2: Cmax,ss of DM-6705

    DM-6705 is a metabolite of delamanid.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  8. Stage 2: Tmax of DM-6705

    DM-6705 is a metabolite of delamanid.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  9. Stage 2: AUC0-24 for DM-6705

    DM-6705 is a metabolite of delamanid.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  10. Stage 2: T1/2,z of DM-6705

    T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) was determined in the terminal phase after drug administration, which was calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  11. Stage 2: Cmax of N-Desmethyl Bedaquiline

    N-Desmethyl Bedaquiline is a metabolite of BDQ.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1

  12. Stage 2: Cmax,ss of N-Desmethyl Bedaquiline

    N-Desmethyl Bedaquiline is a metabolite of BDQ.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  13. Stage 2: Tmax of N-Desmethyl Bedaquiline

    N-Desmethyl Bedaquiline is a metabolite of BDQ.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours (±15 minutes) postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  14. Stage 2: AUC0-24 for N-Desmethyl Bedaquiline

    N-Desmethyl Bedaquiline is a metabolite of BDQ.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14

  15. Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline

    An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all adverse events which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.

    Time frame: From first dose of study drug to end of follow up period (up to 34 days)

  16. Stage 2: Number of Participants With Clinically Significant Vital Sign Changes on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline

    Time frame: From first dose of study drug to end of follow up period (up to 34 days)

  17. Stage 2: Number of Participants With Clinically Significant Changes in ECG Evaluations on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline

    Time frame: From first dose of study drug to end of follow up period (up to 34 days)

Other outcomes

  1. Correlation of QT Interval and Plasma Concentrations of OPC-167832 and/or Delamanid and/or Bedaquiline

    Time frame: Day 1 and Day 14

07

Results

Posted Nov 18, 2023

Participant flow

Participants took part in this study at two investigative sites in South Africa from 18 October 2018 to 11 March 2022.

Participant flow — Overall Study
MilestoneStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZ
Started14141714171414144
Efficacy analysis set/ mitt set14111414151111124
Safety analysis set14141714161313144
Pharmacokinetic (pk) analysis set14141714111313144
Completed1414141316109114
Not completed003114530
Withdrew: Reason not specified003010000
Withdrew: Non-covid related adverse event000100210
Withdrew: Covid related adverse event000003110
Withdrew: Physician decision000001000
Withdrew: Withdrawal by subject000000210

Outcome measures

PrimaryStage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)

Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.

Time frame:
Baseline to Day 14
Reported as:
Mean · sputum log10CFU/mL
Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)
sputum log10CFU/mLStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZ
Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)-1.93 ± 0.98-2.12 ± 1.01-2.08 ± 0.75-1.69 ± 1.15-2.79 ± 0.96
Statistical analysis
  • Stage 1: 10 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.689 · 95% CI 0.485 to 0.939The confidence interval for the EBA ratio is estimated using Fieller's method.
  • Stage 1: 10 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.689 · 95% CI 0.467 to 0.911The confidence interval for the EBA ratio is estimated using Taylor's method.
  • Stage 1: 30 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.759 · 95% CI 0.517 to 1.051The confidence interval for the EBA ratio is estimated using Fieller's method.
  • Stage 1: 30 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.759 · 95% CI 0.497 to 1.020The confidence interval for the EBA ratio is estimated using Taylor's method.
  • Stage 1: 90 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.745 · 95% CI 0.567 to 0.973The confidence interval for the EBA ratio is estimated using Fieller's method.
  • Stage 1: 90 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.745 · 95% CI 0.547 to 0.943The confidence interval for the EBA ratio is estimated using Taylor's method.
  • Stage 1: 3 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.605 · 95% CI 0.353 to 0.896The confidence interval for the EBA ratio is estimated using Fieller's method.
  • Stage 1: 3 mg OPC-167832 vs Stage 1: RHEZ · Eba ratio: 0.605 · 95% CI 0.338 to 0.871The confidence interval for the EBA ratio is estimated using Taylor's method.
PrimaryStage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · nanogram per milliliter (ng/mL)
Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
nanogram per milliliter (ng/mL)Stage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)20.7 ± 6.9253.7 ± 9.16128 ± 50.5391 ± 116157 ± 44.1154 ± 39.6140 ± 41.2
PrimaryStage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng/mL
Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
ng/mLStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)28.2 ± 10.967.3 ± 11.9190 ± 63.6492 ± 99.8208 ± 60.5175 ± 31.3183 ± 51.9
PrimaryStage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Median · hours
Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
hoursStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)3.17 (2.17 to 4.17)4.15 (1.17 to 5.15)3.15 (2.15 to 5.17)3.25 (2.13 to 5.17)2.83 (1.83 to 4.83)3.17 (1.17 to 5.18)3.83 (1.80 to 7.90)
PrimaryStage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
hoursStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)3.17 (1.18 to 5.17)3.15 (1.15 to 5.13)3.13 (2.13 to 5.13)3.17 (2.13 to 5.13)2.83 (1.82 to 5.83)3.13 (2.17 to 4.25)2.83 (1.83 to 4.85)
PrimaryStage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · nanogram.hour per milliliter (ng*h/mL)
Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
nanogram.hour per milliliter (ng*h/mL)Stage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)178 ± 65.1569 ± 1021290 ± 5324050 ± 12401450 ± 3921490 ± 4901420 ± 378
PrimaryStage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng*h/mL
Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
ng*h/mLStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)349 ± 143874 ± 1272490 ± 9285690 ± 10102500 ± 7092020 ± 5632000 ± 730
PrimaryStage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)

T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable from non-compartmental analysis (NCA). The values reported for this outcome measure (OM) are estimates and not actual observed data.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
hoursStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)22.3 (10.3 to 36.7)15.3 (9.2 to 22.5)14.2 (5.6 to 29.1)14.4 (9.8 to 30.1)14.4 (13.3 to 20.4)14.7 (6.2 to 22.1)11.2 (6.8 to 19.1)
PrimaryStage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · mL/minute (min)
Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
mL/minute (min)Stage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)164 ± 62.6195 ± 28.8231 ± 91.8272 ± 53.8215 ± 61.0269 ± 88.5283 ± 103
PrimaryStage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ratio
Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
ratioStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)1.39 ± 0.3811.26 ± 0.1671.56 ± 0.3991.36 ± 0.3621.34 ± 0.3491.23 ± 0.1911.30 ± 0.244
PrimaryStage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ratio
Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
ratioStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)1.99 ± 0.5501.60 ± 0.2892.01 ± 0.5651.55 ± 0.4161.70 ± 0.3781.47 ± 0.3141.36 ± 0.237
PrimaryStage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · (ng/mL)/mg
Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
(ng/mL)/mgStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)9.42 ± 3.636.73 ± 1.196.34 ± 2.125.46 ± 1.116.94 ± 2.025.85 ± 1.046.10 ± 1.73
PrimaryStage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · (ng*h/mL)/mg
Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
(ng*h/mL)/mgStage 1: 3 mg OPC-167832Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)116 ± 47.687.4 ± 12.782.8 ± 30.963.3 ± 11.283.5 ± 23.667.2 ± 18.866.5 ± 24.3
PrimaryStage 2: Cmax of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · ng/mL
Stage 2: Cmax of Delamanid
ng/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax of Delamanid181 ± 41.8198 ± 57.5
PrimaryStage 2: Cmax,ss of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng/mL
Stage 2: Cmax,ss of Delamanid
ng/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax,ss of Delamanid401 ± 102442 ± 188
PrimaryStage 2: Tmax of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Median · hours
Stage 2: Tmax of Delamanid
hoursStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Tmax of Delamanid3.82 (1.83 to 5.83)4.82 (2.83 to 7.90)
PrimaryStage 2: Tmax of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: Tmax of Delamanid
hoursStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Tmax of Delamanid3.83 (1.83 to 5.83)3.83 (2.70 to 7.83)
PrimaryStage 2: AUC0-24 of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · ng.h/mL
Stage 2: AUC0-24 of Delamanid
ng.h/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUC0-24 of Delamanid2140 ± 6132440 ± 957
PrimaryStage 2: AUCτ of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng*h/mL
Stage 2: AUCτ of Delamanid
ng*h/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUCτ of Delamanid5460 ± 16205860 ± 2310
PrimaryStage 2: T1/2,z of Delamanid

T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: T1/2,z of Delamanid
hoursStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: T1/2,z of Delamanid25.4 (16.3 to 38.4)25.1 (17.6 to 56.4)
PrimaryStage 2: CLss/F of Delamanid From Plasma
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · mL/min
Stage 2: CLss/F of Delamanid From Plasma
mL/minStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: CLss/F of Delamanid From Plasma983 ± 264966 ± 330
PrimaryStage 2: RCmax of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ratio
Stage 2: RCmax of Delamanid
ratioStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: RCmax of Delamanid2.26 ± 0.6472.19 ± 0.601
PrimaryStage 2: RAUC of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ratio
Stage 2: RAUC of Delamanid
ratioStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: RAUC of Delamanid2.69 ± 0.6832.49 ± 0.897
PrimaryStage 2: Cmax/Dose of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · (ng/mL)/mg
Stage 2: Cmax/Dose of Delamanid
(ng/mL)/mgStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax/Dose of Delamanid1.34 ± 0.3391.47 ± 0.625
PrimaryStage 2: AUCτ/Dose of Delamanid
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · (ng*h/mL)/mg
Stage 2: AUCτ/Dose of Delamanid
(ng*h/mL)/mgStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUCτ/Dose of Delamanid18.2 ± 5.4019.5 ± 7.71
PrimaryStage 2: Cmax of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · ng/mL
Stage 2: Cmax of Bedaquiline
ng/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax of Bedaquiline5150 ± 18605750 ± 2320
PrimaryStage 2: Cmax,ss of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng/mL
Stage 2: Cmax,ss of Bedaquiline
ng/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax,ss of Bedaquiline5030 ± 18506080 ± 1660
PrimaryStage 2: Tmax of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Median · hours
Stage 2: Tmax of Bedaquiline
hoursStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Tmax of Bedaquiline5.17 (4.13 to 8.15)4.83 (3.82 to 7.90)
PrimaryStage 2: Tmax of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: Tmax of Bedaquiline
hoursStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Tmax of Bedaquiline5.17 (3.15 to 5.20)4.85 (4.83 to 5.82)
PrimaryStage 2: AUC0-24 of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · ng*h/mL
Stage 2: AUC0-24 of Bedaquiline
ng*h/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUC0-24 of Bedaquiline44900 ± 1280047000 ± 15600
PrimaryStage 2: AUCτ of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng*h/mL
Stage 2: AUCτ of Bedaquiline
ng*h/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUCτ of Bedaquiline55900 ± 1600066000 ± 19200
PrimaryStage 2: T1/2,z of Bedaquiline

T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: T1/2,z of Bedaquiline
hoursStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: T1/2,z of BedaquilineNA (14.4 to 139.7)81.1 (54.2 to 155.4)
PrimaryStage 2: CLss/F of BDQ From Plasma
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · mL/min
Stage 2: CLss/F of BDQ From Plasma
mL/minStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: CLss/F of BDQ From Plasma140 ± 85.9109 ± 31.4
PrimaryStage 2: Cmax/Dose of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · (ng/mL)/mg
Stage 2: Cmax/Dose of Bedaquiline
(ng/mL)/mgStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax/Dose of Bedaquiline12.6 ± 4.6215.2 ± 4.14
PrimaryStage 2: AUCτ/Dose of Bedaquiline
Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · (ng*h/mL)/mg
Stage 2: AUCτ/Dose of Bedaquiline
(ng*h/mL)/mgStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: AUCτ/Dose of Bedaquiline140 ± 40.0165 ± 48.0
PrimaryStage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all AEs which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.

Time frame:
From first dose of study drug to end of follow up period (up to 34 days)
Reported as:
Count of participants · Participants
Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)
ParticipantsStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZ
Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)101313111591193
PrimaryStage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Vital Sign Values
Time frame:
From first dose of study drug to end of follow up period (up to 34 days)
Reported as:
Count of participants · Participants
Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Vital Sign Values
ParticipantsStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZ
Heart Rate: > 120 beats per minute (bpm) and >= 15 bpm Change from Baseline110110100
Diastolic Blood Pressure: < 50 mmHg and >= 15 mmHg Decrease from Baseline012100200
Systolic Blood Pressure: < 90 mmHg and >= 20 mmHg Decrease from Baseline132201110
Weight: >= 5% Increase from Baseline342190522
PrimaryStage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Time frame:
From first dose of study drug to end of follow up period (up to 34 days)
Reported as:
Count of participants · Participants
Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
ParticipantsStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZ
Rhythm: Ventricular Premature Beat011010000
ST/T Morphology: Myocardial Ischemia200000000
ST/T Morphology: Symmetrical T-wave Inversion101010000
SecondaryStage 1 and Stage 2: Change From Baseline in Lipoarabinomannan (LAM) in the Mycobacteria Growth Indicator Tube® (MGIT) System

LAM is a key component of the M. tuberculosis cell wall and the decline of sputum LAM concentrations has been shown to correlate closely with CFU decreases in sputum counted on agar media during the first 14 days of TB treatment. Sputum LAM concentration at each collection time point was measured using MGIT system. Baseline LAM was calculated as the log 10 of the average from Day -2 and Day -1 and the change from baseline in log10 was calculated as post-baseline minus baseline for each parameter.

Time frame:
Baseline to Day 14
Reported as:
Mean · log10 LAM picograms (pg)/ml
Stage 1 and Stage 2: Change From Baseline in Lipoarabinomannan (LAM) in the Mycobacteria Growth Indicator Tube® (MGIT) System
log10 LAM picograms (pg)/mlStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Raw-1.52 ± 0.79-1.41 ± 0.75-1.44 ± 0.67-1.35 ± 0.76-1.19 ± 0.75-1.93 ± 1.22-0.97 ± 0.62-2.06 ± 1.03
Processed-1.43 ± 1.07-1.55 ± 0.90-1.40 ± 0.77-1.42 ± 0.74-1.05 ± 0.61-2.05 ± 1.26-0.87 ± 0.66-1.84 ± 1.39
SecondaryStage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System

TTD is the time from start of inoculation of a sputum sample until a MGIT machine detects a positive signal during the 42-day incubation period. One TTD measurement, reported in days and hours was taken at each of the visits at Days -2, -1, 2, 4, 6, 8, 10, 12 and 14. TTD values were then calculated as "days + hours/24" to be used in deriving the analysis values of TTD. Each sample collected from Day -2 to Day 14 were inoculated for 42 days. Baseline TTD was derived using Day -2 and Day -1 MGIT culture with a pure positive result for Mycobacterium tuberculosis. Postbaseline TTD analysis values from Day 1 were derived based on the MGIT culture result as follows: If MGIT culture result was negative for MTB complex, TTD was set to 42 days; If the MGIT culture was pure positive for MTB, but the TTD took longer than 42 days, TTD was capped at 42 days.

Time frame:
Day 1 to Day 14 of treatment period + 42 days of inoculation period (up to 56 days)
Reported as:
Mean · days
Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System
daysStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System4.28 ± 2.889.54 ± 13.6318.15 ± 15.063.33 ± 2.747.44 ± 1.658.93 ± 10.315.33 ± 2.5414.26 ± 13.57
SecondaryStage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA

Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.

Time frame:
Baseline to Day 14
Reported as:
Mean · Sputum log10 CFU/mL
Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA
Sputum log10 CFU/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA-2.17 ± 1.83-1.97 ± 1.29-2.73 ± 1.51
Statistical analysis
  • Stage 2: 30 mg OPC-167832 + 300 mg Delamanid vs Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ · Eba ratio: 1.256 · 95% CI 0.626 to 3.175The confidence interval for the EBA ratio is estimated using Fieller's method.
  • Stage 2: 30 mg OPC-167832 + 300 mg Delamanid vs Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ · Eba ratio: 1.256 · 95% CI 0.362 to 2.151The confidence interval for the EBA ratio is estimated using Taylor's method.
  • Stage 2: 30 mg OPC-167832 + 400 mg BDQ vs Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ · Eba ratio: 1.385 · 95% CI 0.736 to 2.656The confidence interval for the EBA ratio is estimated using Fieller's method.
  • Stage 2: 30 mg OPC-167832 + 400 mg BDQ vs Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ · Eba ratio: 1.385 · 95% CI 0.564 to 2.206The confidence interval for the EBA ratio is estimated using Taylor's method.
SecondaryStage 2: Plasma Concentration of Rifampin
Time frame:
2 hours and 6 hours post-dose on Day 14
Reported as:
Mean · ng/mL
Stage 2: Plasma Concentration of Rifampin
ng/mLStage 2: RHEZ
2 hours Post-dose4020 ± 2450
6 hours Post-dose1880 ± 811
SecondaryStage 1: Plasma Concentration of Isoniazid
Time frame:
2 hours and 6 hours post-dose on Day 14
Reported as:
Mean · microgram per millilitre (ug/mL)
Stage 1: Plasma Concentration of Isoniazid
microgram per millilitre (ug/mL)Stage 1: RHEZ
2 hours Post-dose4.16 ± 1.45
6 hours Post-dose1.58 ± 0.837
SecondaryStage 2: Cmax of DM-6705

DM-6705 is a metabolite of delamanid.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · ng/mL
Stage 2: Cmax of DM-6705
ng/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax of DM-670510.3 ± 10.514.6 ± 11.6
SecondaryStage 2: Cmax,ss of DM-6705

DM-6705 is a metabolite of delamanid.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng/mL
Stage 2: Cmax,ss of DM-6705
ng/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax,ss of DM-670584.0 ± 27.5112 ± 51.9
SecondaryStage 2: Tmax of DM-6705

DM-6705 is a metabolite of delamanid.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: Tmax of DM-6705
hoursStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Day 14.82 (1.83 to 23.63)4.83 (1.83 to 23.58)
Day 144.83 (0.33 to 7.83)4.85 (2.70 to 11.85)
SecondaryStage 2: AUC0-24 for DM-6705

DM-6705 is a metabolite of delamanid.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng*h/mL
Stage 2: AUC0-24 for DM-6705
ng*h/mLStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Day 1103 ± 54.2166 ± 124
Day 141620 ± 4581980 ± 850
SecondaryStage 2: T1/2,z of DM-6705

T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) was determined in the terminal phase after drug administration, which was calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: T1/2,z of DM-6705
hoursStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: T1/2,z of DM-6705NA (90.2 to 509.1)NA (95.8 to 1219.9)
SecondaryStage 2: Cmax of N-Desmethyl Bedaquiline

N-Desmethyl Bedaquiline is a metabolite of BDQ.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Reported as:
Mean · ng/mL
Stage 2: Cmax of N-Desmethyl Bedaquiline
ng/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax of N-Desmethyl Bedaquiline95.4 ± 44.788.2 ± 17.5
SecondaryStage 2: Cmax,ss of N-Desmethyl Bedaquiline

N-Desmethyl Bedaquiline is a metabolite of BDQ.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng/mL
Stage 2: Cmax,ss of N-Desmethyl Bedaquiline
ng/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Cmax,ss of N-Desmethyl Bedaquiline489 ± 154575 ± 112
SecondaryStage 2: Tmax of N-Desmethyl Bedaquiline

N-Desmethyl Bedaquiline is a metabolite of BDQ.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours (±15 minutes) postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Median · hours
Stage 2: Tmax of N-Desmethyl Bedaquiline
hoursStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Day 123.93 (6.17 to 24.05)11.86 (7.82 to 23.88)
Day 1415.08 (0.00 to 48.0)7.83 (3.83 to 23.63)
SecondaryStage 2: AUC0-24 for N-Desmethyl Bedaquiline

N-Desmethyl Bedaquiline is a metabolite of BDQ.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Reported as:
Mean · ng*h/mL
Stage 2: AUC0-24 for N-Desmethyl Bedaquiline
ng*h/mLStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Day 11380 ± 7311410 ± 326
Day 1410100 ± 308011800 ± 1920
SecondaryStage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline

An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all adverse events which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.

Time frame:
From first dose of study drug to end of follow up period (up to 34 days)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
ParticipantsStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline9119
SecondaryStage 2: Number of Participants With Clinically Significant Vital Sign Changes on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
Time frame:
From first dose of study drug to end of follow up period (up to 34 days)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants With Clinically Significant Vital Sign Changes on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
ParticipantsStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Heart Rate: > 120 bpm and >= 15 bpm change from baseline010
Diastolic blood pressure: < 50 mmHg and >= 15 mmHg decrease from baseline020
Systolic blood pressure: < 90 mmHg and >= 20 mmHg decrease from baseline111
Weight: >= 5% increase from baseline052
SecondaryStage 2: Number of Participants With Clinically Significant Changes in ECG Evaluations on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
Time frame:
From first dose of study drug to end of follow up period (up to 34 days)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants With Clinically Significant Changes in ECG Evaluations on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
ParticipantsStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ
Rhythm: Ventricular Premature Beat000
ST/T Morphology: Myocardial Ischemia000
ST/T Morphology: Symmetrical T-wave Inversion000
Other pre-specifiedCorrelation of QT Interval and Plasma Concentrations of OPC-167832 and/or Delamanid and/or Bedaquiline
Time frame:
Day 1 and Day 14

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study drug to end of follow up period (up to approximately 34 days in each Stage 1 and Stage 2). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1: 10 mg OPC-1678320/14 (0%)0/14 (0%)10/14 (71.4%)
Stage 1: 30 mg OPC-1678320/14 (0%)0/14 (0%)13/14 (92.9%)
Stage 1: 90 mg OPC-1678320/17 (0%)0/17 (0%)13/17 (76.5%)
Stage 1: 3 mg OPC-1678320/14 (0%)1/14 (7.1%)10/14 (71.4%)
Stage 1: RHEZ0/16 (0%)0/16 (0%)15/16 (93.8%)
Stage 2: 30 mg OPC-167832 + 300 mg Delamanid0/13 (0%)0/13 (0%)9/13 (69.2%)
Stage 2: 30 mg OPC-167832 + 400 mg BDQ0/13 (0%)2/13 (15.4%)11/13 (84.6%)
Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ0/14 (0%)0/14 (0%)9/14 (64.3%)
Stage 2: RHEZ0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZ
Anal abscessInfections and infestations0/140/140/170/140/160/131/130/140/4
PneumothoraxRespiratory, thoracic and mediastinal disorders0/140/140/170/140/160/131/130/140/4
HaemoptysisRespiratory, thoracic and mediastinal disorders0/140/140/171/140/160/130/130/140/4
Most frequent other events
Showing 10 of 93
Most frequent other events
EventStage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZ
PruritusSkin and subcutaneous tissue disorders1/145/143/172/146/160/131/132/141/4
HeadacheNervous system disorders3/144/142/173/142/162/134/131/140/4
NauseaGastrointestinal disorders1/140/140/171/141/162/130/133/141/4
RashSkin and subcutaneous tissue disorders0/141/140/170/141/161/131/130/141/4
HyperuricaemiaMetabolism and nutrition disorders0/140/140/170/140/160/130/130/141/4
DizzinessNervous system disorders1/141/140/171/141/160/133/131/140/4
Eye PainEye disorders0/143/140/170/140/160/130/130/140/4
VomitingGastrointestinal disorders2/142/140/170/142/161/130/133/140/4
Non-cardiac Chest PainGeneral disorders3/140/140/170/140/160/130/130/140/4
HaemoptysisRespiratory, thoracic and mediastinal disorders1/141/141/170/143/161/130/130/140/4

Baseline characteristics

Randomized Analysis Set included participants who were randomized into the trial.

Age, Continuous
Age, Continuous(years)Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZTotal
Mean31.7 ± 14.634.9 ± 12.836.2 ± 13.337.2 ± 15.633.4 ± 10.934.1 ± 9.929.8 ± 8.930.1 ± 8.231.3 ± 9.533.4 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZTotal
Female48845224138
Male10691012121210384
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZTotal
Hispanic or Latino0000000000
Not Hispanic or Latino14121714151414144118
Unknown or Not Reported0200200004
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stage 1: 10 mg OPC-167832Stage 1: 30 mg OPC-167832Stage 1: 90 mg OPC-167832Stage 1: 3 mg OPC-167832Stage 1: RHEZStage 2: 30 mg OPC-167832 + 300 mg DelamanidStage 2: 30 mg OPC-167832 + 400 mg BDQStage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQStage 2: RHEZTotal
Black or African American8711687109369
Other67589745152
White0010000001
08

Study locations

3 sites
  • University of Cape Town (Pty) Ltd.
    Cape Town, Mowbray 7700, South Africa
  • Satellite Site: Task at Brooklyn Chest Hospital
    Cape Town, 7405, South Africa
  • TASK Clinical Research Centre
    Cape Town, 7530, South Africa
09

References and documents

Publications

  • Shin E, Bhat AG, Ramanathan M. Large Language Models for Clinical Trial Protocol Assessments. Clin Pharmacol Ther. 2026 Feb;119(2):393-402. doi: 10.1002/cpt.70096. Epub 2025 Oct 21. PubMed 41121745 ↗
  • Dawson R, Diacon AH, De Jager V, Narunsky K, Moodley VM, Stinson KW, Liu Y, Zheng B, Hafkin J. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial. Lancet Infect Dis. 2025 Apr;25(4):435-444. doi: 10.1016/S1473-3099(24)00601-7. Epub 2024 Nov 26. PubMed 39612928 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2022, 39 months.

Results were first posted in Nov 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Sep 20, 2018
StartActual
Oct 18, 2018
Primary completionActual
Feb 14, 2022
CompletionActual
Mar 11, 2022
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03678688
Collaborators
Bill and Melinda Gates Foundation
Responsible party
Sponsor
First posted
Sep 20, 2018
Start date
Oct 18, 2018
Primary completion
Feb 14, 2022
Completion
Mar 11, 2022
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Study contacts

Veronique R de Jager, MD
principal investigator · TASK Clinical Research Centre
Prof. Rodney Dawson, MD
principal investigator · University of Cape Town (Pty) Ltd.
Prof. Andreas Diacon
principal investigator · TASK Clinical Research Centre (TCRC)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quabodepistat · OPC-67683

Start the discussion